Kingdon Capital Management’s Aldeyra Therapeutics ALDX Stock Holding History

Kingdon Capital Management’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.65M	Buy	2,652,315 +500,000	+23%	+$860K	0.58%	59
2026 Q1	$3.64M	Buy	2,152,315 +302,315	+16%	+$1.32M	0.4%	56
2025 Q4	$9.58M	Buy	1,850,000 +518,209	+39%	+$2.66M	1.14%	40
2025 Q3	$6.95M	Hold	1,331,791	–	–	0.86%	53
2025 Q2	$5.1M	Buy	1,331,791 +552,791	+71%	+$1.43M	0.69%	54
2025 Q1	$4.48M	Buy	+779,000	New	+$4.6M	0.47%	49

Other funds holding ALDX

KCM

Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Kingdon Capital Management's ALDX Position: Q2 2026 in Review

Kingdon Capital Management increased its Aldeyra Therapeutics (ALDX) stake by 23% in Q2 2026, buying an estimated $860K and bringing the position to 2,652,315 shares worth $5.65M. The position accounts for 0.58% of the portfolio, ranked #59.

Kingdon Capital Management first reported a position in ALDX in Q1 2025 and has held it in 6 quarters since. The position peaked at $9.58M in Q4 2025. 108 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

Kingdon Capital Management held 2,652,315 shares of Aldeyra Therapeutics worth $5.65M as of Q2 2026.
Kingdon Capital Management bought 500,000 Aldeyra Therapeutics shares in Q2 2026, an estimated $860K.
Aldeyra Therapeutics made up 0.58% of Kingdon Capital Management's portfolio in Q2 2026, its #59 holding.
Kingdon Capital Management first reported a position in Aldeyra Therapeutics in Q1 2025 and has held it in 6 quarters since.
Kingdon Capital Management's Aldeyra Therapeutics position peaked at $9.58M in Q4 2025.
108 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on Kingdon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.